LA TIMES: The Food and Drug Administration frequently speeds experimental medicines to sale by approving them before scientific evidence shows they work. For a drug called Tarceva, the FDA’s decisions resulted in thousands of lung cancer patients taking a drug that could not help them. Twelve years passed before the agency warned doctors in October that Tarceva only worked for a small number of patients with a rare gene mutation. Continue reading
KEY TAKEAWAY: Investment in DTC promotion shows no signs of slowing; pharma has been steadily increasing expenditure since 2012, and data for the period October 2015 to September 2016 show a rise of 18% on the previous year With the total for this period reaching $6bn, 2016 looks likely to have been a record year. Continue reading
An Altarum Institute survey found that most consumers seek health care information from providers, friends and family, and online searches. Of all information types, consumers are most dissatisfied with health care cost information . This is especially true for lower-income and uninsured consumers.
KEY TAKEAWAY: Rethinking pharma productivity, an article by McKinsey consulting, is full of corporate consulting gibberish and is proof that they really don’t understand the business of our industry is helping people and helping employees help patients. Continue reading
According to an article in JAMA “more than 4 million children would lose health insurance if the ACA is repealed via budget reconciliation, almost 1 million of these are younger than 5 years”. Continue reading
KEY TAKEAWAY: Deloitte states, in a new report, that returns for pharma are declining and that the pharma industry continues to face regulatory and reimbursement hurdles weighing on the research and development returns. This is partly true. Continue reading
KEY TAKEAWAY:Retail prices for widely used brand name prescription drugs increased substantially faster than general inflation in every year from 2006 to 2015. Between 2014 and 2015, retail prices for 268 brand name prescription drugs widely used by older Americans, including Medicare beneficiaries, increased by an average of 15.5 percent. In contrast, the general inflation rate was 0.1 percent over the same period. Continue reading